The female Gaucher patient: The impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause)

Blood Cells, Molecules, and Diseases

Volumn 43, Issue 3, 2009, Pages 264-288

  Zimran, Ari ^a   Morris, Elizabeth ^b   Mengel, Eugen ^c   Kaplan, Paige ^d   Belmatoug, Nadia ^e   Hughes, Derralynn A ^f   Malinova, Vera ^g   Heitner, Rene ^h   Sobreira, Elisa ⁱ   Mrsić, Mirando ^j   Granovsky Grisaru, Sorina ^a   Amato, Dominick ^k   vom Dahl, Stephan ^l  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e BEAUJON HOSPITAL   (France)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g CHARLES UNIVERSITY   (Czech Republic)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ Genzyme Brazil   (Brazil)

^j KBC Zagreb   (Croatia)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Enzyme replacement therapy; Gaucher disease; Pregnancy; Reproduction

Indexed keywords

ALGLUCERASE; ANTIFIBRINOLYTIC AGENT; IMIGLUCERASE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BONE DISEASE; BONE NECROSIS; BONE PAIN; BREAST FEEDING; DELIVERY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; ENZYME REPLACEMENT; FEMALE FERTILITY; GAUCHER DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MENARCHE; MENOPAUSE; MENORRHAGIA; MENSTRUATION; PARVOVIRUS INFECTION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MENARCHE; MENOPAUSE; MENSTRUATION; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 72149127656     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.04.003     Document Type: Article

References (143)

1. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York, NY 3635-3668
2. Kaplan P., Andersson H.C., Kacena K.A., and Yee J.D. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch. Pediatr. Adolesc. Med. 160 (2006) 603-608
3. Hughes D., Cappellini M.D., Berger M., et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br. J. Haematol. 138 (2007) 676-686
4. Vom Dahl S., Poll L., Di Rocco M., et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr. Med. Res. Opin. 22 (2006) 1045-1064
5. Barton N.W., Brady R.O., Dambrosia J.M., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
6. Grabowski G.A., Barton N.W., Pastores G., et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122 (1995) 33-39
7. Food and Drug Adminstration (FDA). Zavesca prescribing data (2003). http://www.fda.gov/cder/foi/label/2003/21348_zavesca_lbl.pdf http://www.fda.gov/cder/foi/label/2003/21348_zavesca_lbl.pdf (last accessed 03 11 08)
8. European Agency for the Evaluation of Medicinal Products (EMEA). Zavesca prescribing data (2002). http://www.emea.europa.eu/humandocs/PDFs/EPAR/zavesca/H-435-PI-en.pdf http://www.emea.europa.eu/humandocs/PDFs/EPAR/zavesca/H-435-PI-en.pdf
9. Weinreb N.J., Charrow J., Andersson H.C., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113 (2002) 112-119
10. Sims K.B., Pastores G.M., Weinreb N.J., et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin. Genet. 73 (2008) 430-440
11. Pastores G.M., Weinreb N.J., Aerts H., et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 41 (2004) 4-14
12. Weinreb W.J., Aggio M.C., Andersson H.C., et al. International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin. Hematol. 41 (2004) 15-22
13. Andersson H.C., Charrow J., Kaplan P., et al., International Collaborative Gaucher Group U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet. Med. 7 (2005) 105-110
14. Groen J., and Garrer A.H. Adult Gaucher disease with special reference to the variations in its clinical course and the value of sternal puncture as an aid to its diagnosis. Blood. 3 (1948) 1221-1237
15. Gerken H., Graucob E., and Wiedemann H.R. Inheritance in Gaucher's Disease. Br. Med. J. 2 (1964) 1594
16. Zuckerman S., Lahad A., Shmueli A., et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA. 298 (2007) 1281-1290
17. Schneider E.L., Ellis W.G., Brady R.O., et al. Infantile (type II) Gaucher's disease: in utero diagnosis and fetal pathology. J. Pediatr. 81 (1972) 1134-1139
18. Levy-Lahad E., and Zimran A. Gaucher's disease: genetic counselling and population screening. Baillieres Clin. Haematol. 10 (1997) 779-792
19. Food and Drug Administration (FDA). Cerezyme prescribing data (2002). http://www.fda.gov/cder/foi/label/2002/20367slr055_Cerezyme_lbl.pdf http://www.fda.gov/cder/foi/label/2002/20367slr055_Cerezyme_lbl.pdf (last accessed 13 12 07)
20. European Agency for the Evaluation of Medicinal Products (EMEA. Cerezyme prescribing data (2005). http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cerezyme/H-157-PI-en.pdf http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cerezyme/H-157-PI-en.pdf (last accessed 07 11 07)
21. Cox T.M., Aerts J.M., Andria G., and Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26 (2003) 513-526
22. SmPC (Zavesca): http://www.actelion.com/uninet/www/www_main_p.nsf/Content/Zavesca+Summar y+of+Product+Characteristics/$FILE/Zavesca_SmPC.pdf (last accessed April 2008)
23. Granovsky-Grisaru S., Aboulafia Y., Diamant Y.Z., et al. Gynecologic and obstetric aspects of Gaucher's disease: a survey of 53 patients. Am. J. Obstet. Gynecol. 172 (1995) 1284-1290
24. Goldblatt J., and Beighton P. Obstetric aspects of Gaucher disease. Br. J. Obstet. Gynaecol. 92 (1985) 145-149
25. Zlotogora J., Sagi M., Zeigler M., and Bach G. Gaucher disease type I and pregnancy. Am. J. Med. Genet. 32 (1989) 475-477
26. Kauli R., Zaizov R., Lazar L., et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr. Med. Assoc. J. 2 (2000) 158-163
27. Mankin H.J., Trahan C.A., Barnett N.A., et al. A questionnaire study for 128 patients with Gaucher disease. Clin. Genet. 69 (2006) 209-217
28. Beutler E. Gaucher's disease. N. Engl. J. Med. 325 (1991) 1354-1360
29. Bromberg Y.M., Toaff R., and Diengott D. Pregnancy and Gaucher's disease. Br. Med. J. 2 (1953) 761-763
30. Whincup P.H., Gilg J.A., Odoki K., et al. Age of menarche in contemporary British teenagers: survey of girls born between 1982 and 1986. BMJ 322 (2001) 1095-1096
31. De Muinck Keizer-Schrama S.M.P.F., and Mul D. Trends in pubertal development in Europe. Hum. Reprod. Update. 7 (2001) 287-291
32. Chumlea W.C., Schubert C.M., Roche A.F., et al. Age at menarche and racial comparisons in US girls. Pediatrics. 111 (2003) 110-113
33. Juul A., Teilmann G., Scheike T., et al. Pubertal development in Danish children: comparison of recent European and US data. Int. J. Androl. 29 (2006) 247-255 discussion 286-290
34. Norris S. Reproductive infertility: prevalence, causes, trends and treatments. Parliamentary Research Branch, Library of Parliament document, Canada: PRB-0032E (2001). http://dsp-psd.pwgsc.gc.ca/Collection-R/LoPBdP/EB-e/prb0032-e.pdf Available on: http://dsp-psd.pwgsc.gc.ca/Collection-R/LoPBdP/EB-e/prb0032-e.pdf
35. Esplin J., Greenspoon J.S., Cheg E., et al. Alglucerase infusions in pregnant type I Gaucher patients. Blood. 82 (1993) 509
36. Elstein D., Granovsky-Grisaru S., Rabinowitz R., et al. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol. 177 (1997) 1509-1512
37. Rosnes J.S., Sharkey M.F., Veille J.C., and Mueller-Heubach E. Gaucher's disease in pregnancy. Obstet. Gynecol. Surv. 51 (1996) 549-558
38. Aporta Rodriguez R., Escobar Vedia J.L., Navarro Castro A.M., et al. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica. 83 (1998) 852-853
39. Cleary J.E., Burke W.M., and Baxi L.V. Pregnancy after avascular necrosis of the femur complicating Gaucher's disease. Am. J. Obstet. Gynecol. 184 (2001) 233-234
40. Sherer Y., Dulitzki M., Levy Y., et al. Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann. Hematol. 81 (2002) 161-163
41. Elstein Y., Eisenberg V., Granovsky-Grisaru S., et al. Pregnancies in Gaucher disease: a 5-year study. Am. J. Obstet. Gynecol. 190 (2004) 435-441
42. M. Mrsic, K. Fumic, K. Potocki, R. Stern-Padovan. Successful pregnancy of enzyme replacement therapy with Cerezyme [abstract]. Fourth Symposium on Lysosomal Storage Disorders, 2007: March 29-31, 2007; Vienna, Austria: Clin. Ther. 29 (2007) Supp C http://www.clinicaltherapeutics.com/sC_2007/supplc.html:
43. Mengel E, Amraoui Y, Bahlmann F, Paruthiyil L, Beck M. Pregnancy in Gaucher Disease. Presented at the Annual Symposium on Lysosomal Storage Disorders; April 21-23, 2004, Madrid, Spain (unpublished work).
44. Jimenez Saenz M., Romero Castro R., Carrasco Diaz F., and Herrerias Gutierrez J.M. [Gaucher's disease type I, anticoagulant factor and pregnancy]. An. Med. Interna. 8 (1991) 294-295 Spanish
45. Goronov M., Tsvetkov N., and Tomov T. A rare case of a successfully completed pregnancy and Gaucher disease]. Akush Ginekol (Sofia). 332 (1993) 62-63 Bulgarian
46. Simo-Moyo J., Ducloy J.C., Theeten G., et al. Anesthetic management of a pregnant woman with type I Gaucher's disease. Apropos of a case]. Cah Anesthesiol. 42 (1994) 169-172 French
47. Tordjeman N., Monnier J.C., Hautefeuille P., et al. [Gaucher's disease and pregnancy]. J. Gynecol. Obstet. Biol. Reprod. (Paris). 20 (1991) 835-840 French
48. Moughabghab A.V., Fenides A., Hanon F., and Socolovsky C. Gaucher's disease and pregnancy. Acta Anaesthesiol Belg. 45 (1994) 89-92
49. Ayhan A., Tuncer Z.S., and Simsek H. Gaucher's disease and pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 66 (1996) 69-70
50. Clarkson C.P., Magann E.F., Siddique S.A., and Morrison J.C. Hematological complications of Gaucher's disease in pregnancy. Mil. Med. 163 (1998) 499-501
51. Sakarelou N., Kosmaidou Z., Mesogitis S., et al. Pregnancy in Gaucher disease. Eur. J. Obstet. Gynecol. Reprod. Biol. 83 (1999) 113-114
52. Fasouliotis S.J., Ezra Y., and Schenker J.G. Gaucher's disease and pregnancy. Am. J. Perinatol. 15 (1998) 311-318
53. Torloni M.R., Franco K., and Sass N. Gaucher's disease with myocardial involvement in pregnancy. Sao Paulo Med. J. 120 (2002) 90-92
54. S.E. Sozin, I.A. Mihailova, G.N. Salogub. A case of Gaucher disease manifestation in the third trimester of pregnancy. Presented at the Fourth Symposium on Lysosomal Storage Disorders, 2007: March 29-31, 2007; Vienna, Austria: Clin. Ther. 29 (2007) Supp C http://www.clinicaltherapeutics.com/sC_2007/supplc.html:
55. Hunter D., and Evans W. Gaucher's disease 13 years after splenectomy. Proc. Royal Soc. Med. 23 (1929) 224-229
56. Anderson J.P. Hereditary Gaucher's disease. JAMA 101 (1933) 979-981
57. Pool E.H. Gaucher Spleen. Ann. Surg. 74 (1921) 635-637
58. Pool E.H. The results of splenectomy in Gaucher's disease. Surg. Gynec. Obstet. 72 (1941) 807-809
59. Piaggio-Blanco R.A., Codebue J.L., and Pasevro P. Enfermedad de Gaucher y embarazo, con lesions oseas craneanas. Arch Surg Med. 21 (1942) 257-268
60. Groen J. The hereditary mechanism of Gaucher's disease. Blood 3 (1948) 1238-1249
61. Gordon W.H., and Kaufman J.M. Gaucher's disease: discussion and case presentation. J. Mich. Med. Soc. 49 (1950) 785-790
62. Elliott J.F. Gaucher's disease: a case complicated by pregnancy. Can. Med. Assoc. J. 66 (1952) 166-169
63. Logan M.A. Adult Gaucher's disease complicated by thrombocytopenia and pregnancy. J. Fla. Med. Assoc. 40 (1953) 320-323
64. Danopoulos E., and Logothetopoulos J. Klinische und haematologische Beobachtungen an zwei familiaeren Faellen der Gaucherschen Krankheit. Deutsche Arch Klin Med. 201 (1954) 79-88
65. Gerlin G. La maladie de Gaucher (a propos de deux observations personnelles). Algerie Med. 58 (1954) 209-235
66. DeVries A., and Izak G. Thrombocytopenic purpura without anaemia and leukopenia in Gaucher disease. Blood. 10 (1955) 1055-1057
67. Decker B., and McWhorter C.A. Gaucher's disease and pregnancy: two case reports, including observations on the effects of adrenal steroids. Ann. Intern. Med. 44 (1956) 1219-1230
68. Teton J.B., and Treadwell N.C. Gaucher's disease in pregnancy. Am. J. Obstet. Gynecol. 74 (1957) 1363-1366
69. Radman H.M. Gaucher's disease complicating pregnancy. Am. J. Obstet. Gynecol. 75 (1958) 1267-1269
70. Greenwald J.C., and Fenton A.N. Gaucher's disease and pregnancy; report of three cases. Obstet. Gynecol. 14 (1959) 79-85
71. Hoja W.A. Gaucher's disease in pregnancy. Am. J. Obstet. Gynecol. 79 (1960) 286-293
72. Addleman W., and Gold S. Gaucher disease and pregnancy. Can. Med. Assoc. J. 89 (1963) 821-823
73. Watov S.E., and de Sandre R. Gaucher's disease and pregnancy: report of one case involving four pregnancies. Obstet. Gynecol. 23 (1964) 247-250
74. Mendel E.B., and McCullough J.A. Gaucher's disease and pregnancy. Report of a patient during three pregnancies. Obstet. Gynecol. 32 (1968) 607-609
75. Kaminskaia T.P. [Pregnancy and labor in Gaucher's disease]. Akush Ginekol (Mosk). 47 (1971) 70-71 Russian
76. Houlton M.C., and Jackson M.B. Gaucher's disease and pregnancy. Obstet. Gynecol. 51 (1978) 619-620
77. Swinhoe J.R., Cochrane G.W., and Pitkin J. Gaucher's disease in pregnancy associated with intra-uterine growth retardation. Acta. Obstet. Gynecol. Scand. 59 (1980) 375-376
78. Alfano G., Leone G., Mango G., et al. [Gaucher's disease: hemorrhagic diathesis and term pregnancy with the birth of a malformed fetus]. Minerva Med 73 (1982) 899-902 Italian
79. Young K.R., and Payne M.J. Reversible splenic enlargement associated with pregnancy in a patient with Gaucher's disease. J.R. Army Med. Corps. 132 (1986) 157-158
80. Mazor M., Wiznitzer A., Pinku A., et al. Gaucher's disease in pregnancy associated with portal hypertension. Am. J. Obstet. Gynecol. 154 (1986) 1119-1120
81. Müller R., and Giessmann R.U. Gaucher disease and pregnancy - a case report. Zentralbl Gynaekol. 109 (1987) 1453-1456
82. Schoenfeld A., Tepper R., Stein L., et al. Ultrasonographic aspects of Gaucher's disease: report of a patient during three pregnancies. J. Clin. Ultrasound. 15 (1987) 207-210
83. Santana I.B., Soares L., Cardoso M.C., et al. [Gaucher's disease in pregnancy]. Acta Med. Port. 10 (1997) 391-393 Portuguese.
84. Holtkamp W., Kuhn W., Kunze E., and Nagel G.A. [Gaucher disease and pregnancy]. Z Geburtshilfe Perinatol. 192 (1988) 278-281 German
85. Landyshev I.u.S., and Tochilin V.I. [Gaucher's disease and pregnancy]. Ter. Arkh. 61 (1989) 81-83 Russian
86. Menton M., Frauz M., Harzer K., et al. [Gaucher disease and pregnancy]. Geburtshilfe Frauenheilkd. 50 (1990) 410-413 German.
87. Gold E.B., Bromberger J., Crawford S., et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am. J. Epidemiol. 153 (2001) 865-874
88. Zimran A., Abrahamov A., and Elstein D. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy. Isr. Med. Assoc. J. 2 (2000) 80-81
89. Hollak C.E., Corssmit E.P., Aerts J.M., et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am. J. Med. 103 (1997) 185-191
90. Zimran A., Kannai R., Cohen Y., et al. Low dose enzyme replacement therapy for patient's with Gaucher disease: effects of age, sex, genotype and splenectomy on response to treatment in 29 patients. Blood. 82 33A (1993) 82
91. Han J.C., Balagopal P., Sweeten S., et al. Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. J. Clin. Endocrinol. Metab. 91 (2006) 2081-2086
92. Langeveld M., Endert E., Wiersinga W.M., et al. Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J. Inherit. Metab. Dis. 30 (2007) 985
93. Harlow S.D., and Campbell O.M. Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG: Int. J. Obstet. Gynaecol. 111 (2004) 6-16
94. ACOG (American College of Obstetricians and Gynecologists) Committee on Adolescent Health Care. ACOG Committee Opinion No 349. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet. Gynecol. 108 2006 (2006) 1323-1328
95. Schrijver I., Kulm M., Gardner P.I., et al. Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population. J. Mol. Diagn. 9 (2007) 228-236
96. Zimran A., Altarescu G., Rudensky B., et al. Survey of hematological aspects of Gaucher disease. Hematology 10 (2005) 151-156
97. Weinreb N.J., Deegan P., Kacena K.A., et al. Life expectancy in Gaucher disease type 1. Am. J. Hematol. 83 (2008) 896-900
98. Schiffmann R., Mankin H., Dambrosia J.M., et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol. Dis. 28 (2002) 288-296
99. Lachmann R.H., Wight D.G., Lomas D.J., et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. Quart. J. Med. 93 (2000) 237-244
100. Mistry P.K., Sirrs S., Chan A., et al. Pulmonary hyper-tension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol. Gen. Metab. 77 (2002) 91-98
101. Kotsanas D., Al-Souffi M.H., Waxman B.P., et al. Adherence to guidelines for prevention of postsplenectomy sepsis. Age and sex are risk factors: a five-year retrospective review. ANZ J. urg. 76 (2006) 542-547
102. Lellouche F., Belmatoug N., Hutin P., and Valensi F. [Diagnosis of Gaucher disease because of thrombocytopenia in a pregnant woman] Diagnostic de maladie de Gaucher a l'occasion d'une thrombocytopenie chez une femme enceinte. Hematologie 3 3 5 (1999) 233-235 French
103. Ward K.A., Adams J.E., and Mughal M.Z. Bone status during adolescence, pregnancy and lactation. Curr. Opin. Obstet. Gynecol. 17 (2005) 435-439
104. Wenstrup R.J., Kacena K.A., Kaplan P., et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J. Bone Miner. Res. 22 (2007) 119-126
105. Graepel P., Bentley P., Fritz H., et al. Reproduction toxicity studies with pamidronate. Arzneimittelforschung. 42 (1992) 654-667
106. Weinreb N.J., Taylor J., and Cox T. J. et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am. J. Hematol. 83 (2008) 890-895
107. Wilcox J., Treloar A.E., and Sandler D.P. Spontaneous abortion over time: comparing occurrence in two cohorts of women a generation apart. Am. J. Epidemiol. 114 (1981) 548-553
108. Risch H.A., Weiss N.S., Clarke E.A., and Miller A.B. Risk factors for spontaneous abortion and its recurrence. Am J Epidemiol. 128 2 (1988) 420-430
109. Thorstensen K.A. Midwifery management of first trimester bleeding and early pregnancy loss. J. Midwifery Womens Health 45 (2000) 481-497
110. Buss L., Tolstrup J., Munk C., et al. Spontaneous abortion: a prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. Acta. Obstet. Gynecol. Scand. 85 (2006) 467-475
111. Magann E.F., Cummings J.E., Niederhauser A., et al. Antepartum bleeding of unknown origin in the second half of pregnancy: a review. Obstet. Gynecol. Surv. 60 (2005) 741-745
112. Bais J.M., Eskes M., Pel M., et al. Postpartum haemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard (> or = 500 ml) and severe (> or = 1000 ml) postpartum haemorrhage. Eur. J. Obstet. Gynecol. Reprod. Biol. 10 (2004) 166-172
113. Kominiarek M.A., and Kilpatrick S.J. Postpartum hemorrhage: a recurring pregnancy complication. Semin. Perinatol. 31 (2007) 159-166
114. Kramer M.S. The epidemiology of adverse pregnancy outcomes: an overview. J. Nutr. 133 (2003) 1592S-1596S
115. Tracy S.K., Tracy M.B., Dean J., et al. Spontaneous preterm birth of liveborn infants in women at low risk in Australia over 10 years: a population-based study. BJOG: An International Journal of Obstetrics and Gynaecology. 114 (2007) 731-735
116. Weinreb N., Barranger J., Packman S., et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin. Genet. 71 (2007) 576-588
117. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115-137
118. Terk M.R., Esplin J., Lee K., et al. MR imaging of patients with type 1 Gaucher's disease: relationship between bone and visceral changes. Am. J. Roentgenol. 165 (1995) 599-604
119. Heitner R., Arndt S., and Levin J.B. Imiglucerase low-dose therapy for paediatric Gaucher disease - a long-term cohort study. S. Afr. Med. J. 94 (2004) 647-651
120. Zimran A., Elstein D., and Beutler E. Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood. 108 (2006) 802-803
121. Altarescu G., Schiffmann R., Parker C.C., et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells. Mol. Dis. 26 (2000) 285-290
122. Hollak C.E., de Fost M., Aerts J.M., and vom Dahl S. Low-dose versus high-dose therapy for Gaucher disease: goals and markers. Blood. 109 (2007) 387-388
123. de Fost M., Hollak C.E., Groener J.F., et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 108 (2006) 830-835
124. Poll L.W., Koch J.A., Willers R., et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol. Dis. 28 (2002) 209-220
125. G. Grabowski, K. Kacena, C.E. Hollak et al., Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1, Genetis in Medicine 11 (2009) 92-100.
126. Shoenfeld Y., Gallant L.A., Shaklai M., et al. Gaucher's disease: a disease with chronic stimulation of the immune system. Arch. Pathol. Lab. Med. 106 (1982) 388-391
127. Shoenfeld Y., Beresovski A., Zharhary D., et al. Natural autoantibodies in sera of patients with Gaucher's disease. J. Clin. Immunol. 15 (1995) 363-372
128. Billett H.H., Rizvi S., and Sawitsky A. Coagulation abnormalities in patients with Gaucher's disease: effect of therapy. Am. J. Hematol. 51 (1996) 234-236
129. World Health Organization (WHO) Report 2005 Annex 8: selected indicators related to reproductive, maternal and newborn health. http://www.who.int/whr/2005/annex/annexe8_en.pdf.
130. Belizan J.M., Althabe F., and Cafferata M.L. Health consequences of the increasing caesarean section rates. Epidemiology. 18 (2007) 485-486
131. Hollak C.E., Levi M., Berends F., et al. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Brit. J. Haematol. 96 (1997) 470-476
132. Zimran A., Elstein D., Abrahamov A., et al. Significance of abnormal neutrophil chemotaxis in Gaucher's disease. Blood. 84 (1994) 2374-2375
133. Starzyk K., Richards S., Yee J., et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol. Genet. Metab. 90 (2007) 157-163
134. Clapp 3 rd J.F., Seaward B.L., Sleamaker R.H., and Hiser J. Maternal physiologic adaptations to early human pregnancy. Am. J. Obstet. Gynecol. 159 (1988) 1456-1460
135. vom Dahl S., Poll L.W., and Häussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br. J. Haematol 113 (2001) 1084-1087
136. Toth J., Erdos M., and Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur. J. Haematol. 70 (2003) 125-128
137. Cox T.M., Aerts J.M.F.G., Belmatoug N., et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J. Inher. Met. Dis. 31 (2008) 319-336
138. Maas M., Hollak C.E., Akkerman E.M., et al. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am. J. Roentgenol. 179 (2002) 961-965
139. van Breemen M.J., de Fost M., Voerman J.S., et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim. Biophys. Acta. 1772 (2007) 788-796
140. Guffon N. Gaucher disease and chitotriosidase. Rev. Med. Interne. 27 (2006) S26-29 French
141. Kalkwarf H.J., and Specker B.L. Bone mineral changes during pregnancy and lactation. Endocrine. 17 (2002) 49-53
142. Barlow D.H. Osteoporosis guidelines. Climacteric. 10 (2007) 79-82
143. Mistry P.K., Sadan S., Yang R., et al. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am. J. Hematol. 82 (2007) 697-701